Soliqua 100/33 100 U/mL
insulin glargine and lixisenatide · INJECTION, SOLUTION · Sanofi-Aventis U.S. LLC
Soliqua 100/33 is a injection, solution containing insulin glargine and lixisenatide at 100 U/mL, taken subcutaneous. Manufactured by Sanofi-Aventis U.S. LLC.
Key Facts
- Brand Name
- Soliqua 100/33
- Generic Name
- insulin glargine and lixisenatide
- NDC Code (Product)
0024-5761- Manufacturer
- Sanofi-Aventis U.S. LLC
- Strength
- 100 U/mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA208673
- Drug Class
- Insulin Analog [EPC]; GLP-1 Receptor Agonist [EPC]
- Marketing Start
- 11/21/2016
Recall History
No Recall HistoryFrequently Asked Questions
What is Soliqua 100/33 used for?
Soliqua 100/33 contains insulin glargine and lixisenatide. It is a injection, solution taken subcutaneous. Consult your doctor for specific uses.
Is Soliqua 100/33 a controlled substance?
Soliqua 100/33 is not classified as a controlled substance by the DEA.
What is the generic name for Soliqua 100/33?
The generic name for Soliqua 100/33 is insulin glargine and lixisenatide. There are no other listed brand versions of insulin glargine and lixisenatide.
What is the NDC code for Soliqua 100/33 100 U/mL?
The NDC (National Drug Code) for Soliqua 100/33 100 U/mL is 0024-5761, listed by Sanofi-Aventis U.S. LLC.
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)